NCT00002329已完成1 期
A Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Oral Dose-Tolerance Study of Oral MDL 28,574A Solution in HIV-Positive Patients
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 2
研究概览
简要总结
To characterize the safety profile of MDL 28574A following both acute and subchronic dosing in HIV-positive patients. To determine the MTD of both acute and subchronic doses of this drug when administered as oral solution. To determine the pharmacokinetic profile of MDL 28574A and castanospermine (from which MDL 28574A is derived) following both acute and subchronic dosing.
详细描述
In Part A of the study, patients receive a single oral dose of MDL 28574A on day 1 and are followed through day 7. In Part B, patients receive single daily doses of the drug on days 1 through 14 and are followed through day 21.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have:
- •HIV infection.
- •CD4 count >= 500 cells/mm
- •No evidence of AIDS.
- •No antiretroviral therapy within 30 days prior to study entry.
- •Presence of lymphadenopathy in two or more extrainguinal sites, at least 1 cm in diameter for 3 or more months, is permitted.
排除标准
- •Co-existing Condition:
- •Patients with the following symptoms or conditions are excluded:
- •Clinically significant abnormalities on routine hematology (other than CD4 count and Western blot), serum chemistry, and urinalysis.
- •Abnormal EKG.
- •Positive stool guaiac.
- •Abnormal medical history or physical exam including temperature, heart rate, and blood pressure.
- •Clinically significant organ abnormality or disease.
- •Positive urine drug screen for illicit drugs.
- •Inability to comply with study procedures.
- •Concurrent Medication:
- •Routine treatment with nonprescription medications.
- •Treatment with other medications except with approval of the investigator.
- •Patients with the following prior conditions are excluded:
- •Prior participation in this trial.
- •Serious physical or mental illness within 1 year prior to study entry that would confound interpretation of data.
- •Prior Medication:
- •Antiretroviral therapy within 30 days prior to study entry.
- •Known medications that alter renal, hepatic, or hematologic/immunologic function (such as barbiturates, phenothiazines, cimetidine, and immunomodulators) within 14 days prior to study entry.
- •Routine treatment with nonprescription medications within 3 days prior to study entry.
- •History of alcohol or drug abuse within the past year.
研究者
研究点 (2)
Loading locations...
相似试验
暂停
2 期
A Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and LamivudineHIV InfectionsNCT00002424Merck Sharp & Dohme LLC186
已完成
1 期
A Study of AMD11070 in HIV-infected Patients Carrying X4-tropic VirusX4 Tropic VirusHIV InfectionsNCT00361101Genzyme, a Sanofi Company10
已完成
1 期
Safety and Efficacy of BAY 50-4798 in Patients With HIV InfectionHIV InfectionsNCT00059462Bayer56
已完成
3 期
The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken ZidovudineHIV InfectionsNCT00002371Bristol-Myers Squibb80
已完成
2 期
A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected PatientsHIV InfectionsNCT00002390Glaxo Wellcome